Quantcast
Last updated on April 25, 2014 at 1:22 EDT

Latest Vancomycin Stories

2012-04-02 02:28:43

CHICAGO, April 2, 2012 /PRNewswire-USNewswire/ -- MRSA, the antibiotic resistant staph bacteria that has been a secret and silent killer in healthcare facilities for decades is at epidemic levels worldwide. MRSA Survivors Network, a global leader in the fight for MRSA awareness, education and prevention launches this week - "International MRSA Testing Week, April 1-7th" a new global campaign with the slogan "Prevention Saves Lives" that draws critical attention for the need of...

2012-03-30 14:21:37

SAN DIEGO, March 30, 2012 /PRNewswire/ -- Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) announced the presentation of results from a post-hoc subgroup analysis of the company's two large Phase 3 trials which demonstrated that cancer patients with Clostridium difficile-associated diarrhea (CDAD) had higher clinical cure rates, better sustained response and lower recurrence when treated with DIFICID® (fidaxomicin) tablets compared to oral vancomycin. The data will be presented at...

2012-03-30 14:21:31

STAINES, UK, March 31, 2012 /PRNewswire/ -- Clostridium difficile infection (CDI), a potentially fatal disease, is one of the most common healthcare acquired infections in Europe[1] New data presented at the 22nd European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) demonstrate that in cancer patients with CDI, DIFICLIR( fidaxomicin) may offer significant benefits in terms of clinical cure*, recurrence[#] and sustained clinical...

2012-03-26 02:23:01

SAN DIEGO, March 26, 2012 /PRNewswire/ -- Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) announced today The Lancet Infectious Diseases has published results from the European and North American Phase 3 trial evaluating the safety and efficacy of DIFICID® (fidaxomicin) tablets in the treatment of adult patients with Clostridium difficile infection (CDI). The Phase 3 non-inferiority trial showed that DIFICID had similar clinical cure rates as oral vancomycin in the initial treatment...

2012-02-01 11:01:00

AUSTIN, TX and TORONTO, ON, Feb. 1, 2012 /PRNewswire/ - Affinium Pharmaceuticals announced today dosing of the first patient in a multi-center Phase 2 clinical trial evaluating oral AFN-1252 in acute bacterial skin & skin structure infections ("ABSSSI").  The Phase 2 trial is the first human efficacy study conducted with this new class of antibiotic and follows the recently completed Phase 1 trials which demonstrated excellent safety, tolerability and pharmacokinetics of...

2012-01-05 15:30:00

EXTON, Pa., Jan. 5, 2012 /PRNewswire/ -- ViroPharma Incorporated (Nasdaq: VPHM) today announced that Vincent Milano, president and chief executive officer of ViroPharma, will provide an overview of the company's business during the 30th Annual J.P. Morgan Healthcare Conference. The presentation will be webcast live at 7:30 P.M. ET (4:30 P.M. PT) on Tuesday, January 10, 2012 and may be accessed via the company's website at www.viropharma.com. The conference is being...

2011-12-21 08:00:00

Embrace Health, Inc. announces the launch of its new Recovery Program for MRSA / Staph infections on 30 November 2011. Port Townsend, WA (PRWEB) December 21, 2011 Embrace Health, Inc. (a leader in Staph Infection and MRSA Treatment education online since 2008) announced a new educational program [launched worldwide on November 30, 2011] called the Recovery Program exclusively for sufferers of Staph Infections. This Staph Infection resource is a comprehensive collection of educational works...

2011-12-14 13:30:00

EXTON, Pa., Dec. 14, 2011 /PRNewswire/ -- ViroPharma Incorporated (Nasdaq: VPHM) today announced the modernization of labeling for Vancocin® (vancomycin hydrochloride, USP) Capsules made effective through the U.S. Food and Drug Administration's (FDA) approval of a supplemental new drug application (sNDA). The company also provided updates on ViroPharma's ongoing citizen petition and litigation with the FDA regarding Vancocin. Vancocin Labeling...

2011-12-12 07:00:00

SAN DIEGO, Dec. 12, 2011 /PRNewswire/ -- Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) and Astellas Pharma Europe Ltd., a European subsidiary of Tokyo-based Astellas Pharma Inc. (Tokyo: 4503) announced today that the European Commission has granted Marketing Authorization (MA) for DIFICLIR(TM) (fidaxomicin) tablets for the treatment of adults with Clostridium difficile infections (CDI) also known as Clostridium difficile-associated diarrhea (CDAD). CDI is a significant problem in...

2011-12-06 07:00:00

SAN DIEGO, Dec. 6, 2011 /PRNewswire/ -- Optimer Pharmaceuticals, Inc. (Nasdaq: OPTR) announced today that data being presented at the American Society of Health-System Pharmacists 46th Midyear Clinical Meeting demonstrate that the economic value of DIFICID® (fidaxomicin) tablets to the U.S. health system meets or exceeds the price per day to treat Clostridium difficile-associated diarrhea (CDAD) compared to vancomycin. Results showed that when data accounting...


Latest Vancomycin Reference Libraries

0_4d46cc72a490344d44ba78359f528175
2011-04-26 21:07:20

Enterococcus is a Gram-positive, commensal bacterium inhabiting the gastrointestinal tracts of humans and other mammals. It is a main constituent of some probiotic food supplements. E. faecalis can cause life-threatening infections in humans, especially in the nosocomial environment, where the naturally high levels of antibiotic resistance found in E. faecalis contribute to its pathogenicity. It is frequently found in root canal-treated teeth in prevalence values ranging from 30% to 90% of...

0_71ad70ea6f0948a7e84406e760c7f5a4
2011-04-15 14:36:05

Enterococcus faecalis "“ formerly classified as part of the Group D Streptococcus system "“ is a Gram-positive, commensal bacterium inhabiting the gastrointestinal tracts of humans and other mammals. It is one of the main constituents of some probiotic food supplements. E. faecalis can cause life-threatening infections in humans. It is frequently found in root canal-treated teeth in prevalence values ranging from 30% to 90% of the cases. It is a non-motile, facultatively anaerobic...

More Articles (2 articles) »